BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Chiltern International Ltd. Announces The Consolidation Of Existing Investor Base


12/17/2013 9:53:08 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

LONDON
and WILMINGTON, N.C., Dec. 17, 2013 /PRNewswire/ -- Chiltern International Limited ("Chiltern" or "the Company"), a global contract research organization (CRO), announces the consolidation of the ownership of existing investors, led by interests associated with Sir Douglas Myers. This consolidated investor base enables Chiltern to continue to deliver on its strategic plan for growth while maintaining its focus on the delivery of high quality, innovative clinical trial services and therapeutic expertise.

The new ownership structure offers greater access to new investment to further the development of Chiltern. It will provide Chiltern with the means to expand further and develop within key target markets, both organically and through investment in people, technology and client relationships, as well as external opportunities to optimize Chiltern's mid-tier leadership position through carefully targeted acquisitions.

Demand for Chiltern's services is at an all-time high: the Company announced a record financial performance in the year ended March 2013, with top line growth of 16.8% to £104m, taking the five year revenue CAGR to 15.3% for 2008-2013. The new investment will allow Chiltern to maintain this substantial growth and to continue to drive the Company forward.

The global CRO market is expected to show continued growth as the pharmaceutical industry responds to significant sector challenges. These include the growing pressure to increase R&D productivity, the rising cost and complexity of clinical trials, increasing regulatory hurdles, and a desire to shift fixed to variable cost. These industry drivers represent a significant opportunity for Chiltern.

Nick Thornton, Chairman of Chiltern, said: "This new investment is a significant milestone in Chiltern's history. For over 30 years, Chiltern's success has been underpinned by a tradition of ownership led by private investment. We have continued to grow our market share as our customers have increasingly sought mid-tier global CROs with the ability to deliver better value and a comprehensive range of high quality services."

Jim Esinhart, CEO of Chiltern, said: "This investment will allow us to continue to invest in organic growth and explore external acquisition opportunities. I am excited to be leading Chiltern to the next phase of growth. Our mission has not changed we are committed and will continue to deliver expert, high quality, clinical development services around the world whilst building trustworthy and lasting relationships, understanding each customer's specific needs and, overall, improving the quality of life."

Company profile:

About Chiltern:
Established in 1982, Chiltern is a leading global clinical CRO with extensive experience in the management of Phase I-IV clinical trials across a broad range of therapeutic areas, functional service provision and contract staffing solutions. Chiltern has conducted trials in more than 40 countries, employs more than 1,600 people globally and offers services in Early Phase, Global Clinical Development, Late Phase, Biometrics, Medical and Regulatory Affairs and Resourcing Solutions. Chiltern prides itself as a development partner that offers flexibility, responsiveness and quality delivery. For further information: www.chiltern.com.

For more information contact:




Natalie Chong

Susan Ojanen

Marketing Director

Marketing Executive

Chiltern International Ltd.

Chiltern International Inc.

171 Bath Road

1241 Volunteer Parkway

Slough

Suite 950

Berkshire SL1 4AA

Bristol, TN 37620

UNITED KINGDOM

USA

Tel: +44 (0) 1753 512 000

Tel: +1 (423) 968 9533

Email: natalie.chong@chiltern.com

Email: susan.ojanen@chiltern.com





For financial enquiries contact:




John Dineen

Ben Atwell

Senior Director

Senior Managing Director

FTI Consulting

FTI Consulting

Holborn Gate

Holborn Gate

26 Southampton Buildings

26 Southampton Buildings

London WC2A 1PB

London WC2A 1PB

UNITED KINGDOM

UNITED KINGDOM

Tel: +44 (0) 20 7269 7193 direct

Tel: +44 (0) 20 7269 7242 direct

Fax: +44 (0) 203 077 0519

Fax: +44 (0) 203 077 0519

Email: John.Dineen@fticonsulting.com

Email: Ben.Atwell@fticonsulting.com

SOURCE Chiltern



Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES